Johnson & Johnson announced that their drug combination RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGFR mutations. This result, presented at ASCO 2026, marks a significant improvement over current treatments, which typically offer less than two years of survival. The combination targets multiple disease drivers and showed consistent responses across mutation subgroups, including those with historically poor outcomes. These findings reinforce the potential of RYBREVANT-based regimens as a durable first-line treatment option for this difficult-to-treat cancer subtype.
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
